Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 13/20 | 0.55 |
| ▸ | ESR1 | P03372 | 5/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.42 |
| ▸ | HTR3B | O95264 | 4/20 | 0.42 |
| ▸ | HTR3A | P46098 | 4/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497200 | 0.90 | KDM4E (0.51) | ESRRGESR1ESR2PTPN1PTPN11 | |
| SCHEMBL6498807 | 0.90 | MAPK11 (0.43) | ESRRGESR1ESR2PTPN1PTPN11 | |
| SCHEMBL6489244 | 0.90 | ESRRG (0.46) | ESRRGESR1ESR2PTPN1PTPN11 | |
| SCHEMBL6486663 | 0.90 | ESRRG (0.46) | ESRRGESR1ESR2PTPN1PTPN11 | |
| SCHEMBL6497432 | 0.89 | CHRNA7 (0.54) | ESRRGESR1ESR2PTPN1PTPN11 | |
| SCHEMBL6485890 | 0.89 | HPGDS (0.49) | ESRRGESR1ESR2CHRNA7HTR3E | |
| SCHEMBL6491196 | 0.87 | KDM4E (0.55) | ESRRGESR1ESR2PTPN1PTPN11 | |
| SCHEMBL6489478 | 0.86 | KDM4E (0.44) | ESRRGESR1ESR2PTPN1PTPN11 | |
| SCHEMBL6487135 | 0.84 | ESRRG (0.50) | ESRRGESR1ESR2CHRNA7HTR3E | |
| SCHEMBL6487853 | 0.84 | RXFP1 (0.47) | ESRRGESR1ESR2CHRNA7HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | claimed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | ESRRG 3073/4885ESR1 4371/4885ESR2 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.